Novel Treatments in Lung Cancer See Expanded Use

January 4, 2019

By: Graham T. Watson, MD – Virginia Oncology Associates

The quickly expanding knowledge of cancer biology has led to new, highly effective treatments for patients with non-small cell lung cancer. Advances in genetics have brought about targeted therapy with drugs that “target” a specific driver mutation. With deeper understanding of the immune system’s interaction with cancer cells, we can uncloak cancer cells that previously hid from immune destruction. For years, we have leveraged these therapies only in Stage IV lung cancer, but research has shown that that Stage III patients treated first with chemoradiotherapy can also gain benefit.

 Immunotherapies such as nivolumab (Opdivo®) or pembrolizumab (Keytruda®) have helped patients with incurable, Stage IV, lung cancer live longer. While these drugs represent a major breakthrough, limiting their use to Stage IV patients is a frustration for both patients and doctors. While the goal of treatment in Stage III lung cancer patients is cure, the rates of recurrence are high. Finding treatment that can reduce this risk of recurrence is a worthy goal.

Read More Categories: Lung Cancer, Cancer Research, Cancer Treatment

What Does the Great American Smokeout Have to Do with Lung Cancer Risk?

November 13, 2017

What is the American Cancer Society's Great American Smokeout? It's an annual event, held the third Thursday of every November, a date on which smokers nationwide are asked to give up smoking. Quitting for just one day helps you take action toward a healthier life, and reduce your lung cancer risk.

Each year, the Great American Smokeout calls attention to the deaths, lung cancer diagnosis and other chronic diseases that smoking causes, and how to prevent them. As a result of this event, there have been actions taken towards reducing the health impacts that smoking can have on smokers and non-smokers including:

Read More Categories: Cancer Prevention, Lung Cancer

1